A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Hol
- Kína53 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 199 fő, tervezett
- Kezdés
- 2025. ápr. 30.
- Várható befejezés
- 2027. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- TQB3473 Tablets
- TQB3473 Placebo
- A regiszteradat frissítve
- 2025. május 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with long-lasting primary immune thrombocytopenia (ITP, low platelets caused by the immune system). Earlier treatments must not have worked or the disease came back.
- Életkor
- 18 to 75 years
- Nem
- All sexes can join.
- A betegség stádiuma
- Primary ITP diagnosed at least 12 months ago. ECOG score 0-1 (able to do daily activities). No severe bleeding in the 4 weeks before screening.
- Korábbi kezelés
- Must have had glucocorticoids and at least one standard ITP treatment that did not work or after which the disease came back. Cannot join after earlier treatment with Syk inhibitors.
- Biomarker vagy leletérték
- Average of at least three platelet counts, taken more than 3 days apart in the last 3 months, below 30×10^9/L, with no count above 35×10^9/L.
A részvétel fő kizáró okai
- ITP caused by another disease or by a drug, or Evans syndrome
- Blood cancers, bone marrow diseases, or other cancers in the past 3 years, with some exceptions
- Earlier bone marrow, stem cell or major organ transplant
- Bleeding in the brain or other serious bleeding, or blood clots in the past 12 months
- Recent platelet-raising treatments, rituximab, spleen removal or vaccination within the set time limits
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects voluntarily join this study, sign the informed consent form (ICF), and demonstrate good compliance
- Male or female subjects aged 18 to 75 years (calculated based on the date of signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score of 0-1
- Diagnosis of primary ITP prior to randomization, with a duration of ≥12 months
- An average of at least three independent platelet counts (spaced more than 3 days apart) within the 3 months prior to randomization <30×10\^9/L, with no count >35×10\^9/L; and no severe bleeding within 4 weeks prior to screening
- Previous treatment with glucocorticoids and at least one standard ITP therapy that was ineffective or resulted in relapse
- Female subjects of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of study treatment, with a negative serum or urine pregnancy test within 7 days prior to study enrollment; male subjects must agree to use effective contraception during the study and for 6 months after the end of study treatment, as detailed in Section 5.5
Ki nem vehet részt
- History of or concurrent other malignancies within the past 3 years. Exceptions include: other malignancies treated with a single surgical procedure and achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)]
- Previous bone marrow/hematopoietic stem cell transplantation or major solid organ transplantation
- Vaccination within 8 weeks prior to randomization or planned vaccination during the study period
- Major surgical treatment or significant traumatic injury within 4 weeks prior to randomization, or anticipated need for major elective surgery during the study treatment period (major surgery is defined as level 3 or higher according to the National Surgical Classification Catalog 2022)
- History of intracranial hemorrhage or other severe bleeding in vital organs (≥CTCAE grade 3), or symptomatic gastrointestinal bleeding (e.g., hematemesis, melena, etc., excluding asymptomatic "occult blood test positive" and hemorrhoids) within 6 months prior to screening
- Arterial/venous thrombotic events within 12 months prior to randomization, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
- Known allergy to the active ingredient or excipients of the investigational drug
- Previous treatment with Syk inhibitors
- Participation in another clinical trial and use of investigational drugs within 4 weeks prior to randomization
- Evidence of secondary causes of ITP (e.g., untreated Helicobacter pylori infection, leukemia, lymphoma, history of autoimmune diseases such as systemic lupus erythematosus, Hashimoto's thyroiditis, etc.) or drug-induced causes (e.g., anticonvulsants, antibiotics, heparin, etc.), or immune-mediated cytopenia involving two or more cell lines such as Evans syndrome or immune-related cytopenia
- Subjects with a history or current diagnosis of myelofibrosis, myelodysplastic syndrome, aplastic anemia, lymphoproliferative disorders, or other malignant hematologic diseases
- Conditions affecting venous blood sampling or multiple factors affecting oral medication (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.)
- Any condition judged by the investigator to pose a significant risk to the subject's safety or to affect the subject's ability to complete the study
- Adverse reactions from previous treatments have not resolved to ≤CTCAE grade 1, except for non-clinically significant and asymptomatic laboratory abnormalities judged by the investigator to pose no safety risks
- ITP-related symptoms and treatments:; Receipt of immunoglobulins or platelet transfusions within 2 weeks prior to randomization; Receipt of treatments aimed at increasing platelet counts (including but not limited to glucocorticoids, Thyroid peroxidase (TPO), Thrombopoietin receptor agonists (TPO-RAs), cyclosporine, herbal medicines, etc.) within 4 weeks prior to randomization, except for those meeting inclusion criterion (8); Use of rituximab or other anti-cluster of differentiation 20 (CD20) drugs within 14 weeks prior to randomization; Splenectomy within 12 weeks prior to randomization
- Need for long-term/continuous use of medications affecting platelet function [including but not limited to aspirin, clopidogrel, ticagrelor, non-steroidal anti-inflammatory drugs (NSAIDs), etc.] or anticoagulant therapy
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment.
A teljes eredeti leírásKevesebb
The study consists of a treatment period and a safety follow-up period.
A vizsgálat 2 csoportja
- TQB3473 TabletsMár használt kezelés, összehasonlításként
TQB3473 Tablets 600 mg orally once daily for 24 consecutive weeks.
- TQB3473 PlaceboPlacebo, összehasonlításként
Placebo, orally once daily for 24 consecutive weeks.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (ITP)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06900920: ki vehet részt
- A regiszteradat frissítve
- 2025. május 20.